Targeted Therapy | Novartis

Media Release
Jun 01, 2023
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
Story
Jun 13, 2022
Prostate Cancer: A collective commitment to serving underserved communities
Media Release
Nov 08, 2021
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
Media Release
Sep 29, 2021
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
Media Release
Sep 29, 2021
New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis
Media Release
Sep 30, 2021
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
Media Release
Dec 09, 2019
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Media Release
Jan 06, 2020
Novartis completes tender offer for all outstanding shares of The Medicines Company
Media Release
Jan 06, 2020
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
Story
Jun 03, 2016
Your Genes, Your Melanoma
Story
Feb 24, 2017
Meet T.J. Sharpe
Story
Feb 12, 2014
Talking to: Ann Aerts, Head of the Novartis Foundation